Clindamycin, which is usually used in combination with pyrimethamine, has been proven effective in the treatment of cerebral toxoplasmosis in human immunodeficiency virus-infected patients. However, it is not known if clindamycin achieves inhibitory concentrations at the site of infection. Also, it has been hypothesized that the activity of clindamycin against Toxoplasma gondii may be due, at l...

A retrospective study was conducted to assess the relationships between clindamycin resistance in members of the Bacteroides fragilis group, previous antimicrobial therapy, and the context for the development of infection, whether in the community or during hospitalization. Eighty-five clindamycin-resistant clinical strains (one isolate per patient) isolated from January 1988 to October 1994 we...

Increasing frequency of methicillin resistant Staphylococcus aureus (MRSA) infections and changing patterns in antimicrobial resistance have led to renewed interest in the use of macrolide-lincosamide-streptogramin (MLS) antibiotics to treat such infections. Inducible macrolides, lincosamides, type B streptogramins (MLS(Bi)) resistance has to be identified to avoid clinical failure of clindamyc...

Clindamycin has been used to treat serious infections caused by susceptible Staphylococcus aureus strains in children for more than 30 years. It remains effective for many infections caused by community-acquired methicillin-resistant S. aureus (CAMRSA). Clindamycin also is useful for selected infections caused by pneumococci, group A streptococci, and a number of other microbes. Absorption afte...

Sir, Recently in Australia, prescribing patterns for lincosamides have changed. Parenteral lincomycin use now exceeds parenteral clindamycin use in hospitals, including intensive care units. The reasons pertain to availability, cost and the recommendations of the national antibiotic guidelines. The Australian therapeutic guidelines present lincomycin and clindamycin as equivalent treatments for...

We report a case of a surgical site infection caused by clindamycin-susceptible, erythromycin-resistant methicillin-resistant Staphylococcus aureus (MRSA) that did not respond to treatment with clindamycin. The MRSA isolate obtained after treatment was resistant to clindamycin but was found to be identical by pulsed-field gel electrophoresis to the clindamycin-susceptible isolate obtained befor...

Culture Streptomyces coelicolor Muller NRRL3532 deactivates clindamycin. The inactive compound identified as clindamycin-3-phosphate on treatment with dephosphorylating enzymes affords the active compound, clindamycin. In as much as the 2-phosphate ester of clindamycin is being clinically evaluated as an injectable form of clindamycin, it was of interest to compare its in vitro and in vivo char...

A rabbit model for Staphylococcus aureus osteomyelitis was used to compare treatment with clindamycin and cefazolin. Cefazolin (5 mg/kg), cefazolin (15 mg/kg), and clindamycin (70 mg/kg) were injected subcutaneously every 6 h for 28 days. After treatment, S. aureus was found in bone cultures from 22 of 23 control rabbits, 12 of 22 rabbits treated with cefazolin (5 mg/kg), 12 of 23 rabbits treat...

Background. Current susceptibility testing recommendations for β-hemolytic streptococci outline testing for clindamycin resistance, including inducible resistance by a positive D-zone phenotype. However, few studies describe the prevalence of clindamycin resistance among invasive GCS and GGS organisms. This study aims to describe the prevalence of clindamycin resistance among GCS/GGS compared w...